MAPT and Alzheimer disease: Previous studies indicated that reduction of Aβ peptides and increase of phosphorylated tau peptides in the cerebrospinal fluid (CSF) serve as biomarkers to confirm the diagnosis of probable AD (Olsson et al., 2016).